We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Worried about your State Pension income? Here are 2 FTSE 100 dividend stocks I’d buy today

These two FTSE 100 (INDEXFTSE:UKX) stocks could deliver improving income returns in my opinion.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

With the State Pension amounting to just £8,767 per year, many retirees are likely to need a second income in older age.

Since the FTSE 100 appears to offer good value for money at the present time, with it having a dividend yield of around 4.5%, there are a number of opportunities to generate a growing passive income across the large-cap share universe.

Should you buy AstraZeneca Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

With that in mind, here are two FTSE 100 stocks that could offer an improving income outlook, as well as relatively stable financial performance over the long term.

AstraZeneca

It’s been a difficult journey for pharmaceutical company AstraZeneca (LSE: AZN) over the last decade. It has seen its profitability fall heavily due to the loss of patents on key drugs, with this leading to a lack of dividend growth in recent years.

Now though, the company appears to be in a relatively strong position. It has invested heavily in its pipeline under a strategy that has sought to focus on core growth areas. This strategy is now expected to bear fruit, with the business forecast to post a rise in net profit of around 12% in the current year.

This could stimulate AstraZeneca’s dividend growth prospects, and lead to an improving income outlook for its investors. It now has a dividend yield of just 3.4%, but its potential to increase dividends at a pace that exceeds inflation could lead to a robust outlook from an income perspective.

Alongside this, the company’s defensive appeal could help it to outperform the wider FTSE 100 at a time when the prospects for the global economy remain highly uncertain.

Unilever

Unilever’s (LSE: ULVR) recent updates have shown that its current growth strategy is paying off. It has focused investment on fast-growing markets across the emerging world, with them now making up the lion’s share of its revenue. They are also the main catalyst behind the company’s growth rate, and are likely to remain so over the medium term as wages in countries such as China move higher at a rapid rate.

Like AstraZeneca, Unilever’s dividend yield is below that of the wider FTSE 100 at the present time. The consumer goods company is set to record an income return of just 2.9% in the current year. However, with its bottom line forecast to produce a gain of 10% this year and its dividend payments being covered 1.6 times by profit, the scope for a rapidly-rising dividend seems to be high.

Although Unilever may lack the defensive appeal of some of its FTSE 100 peers, its potential to enjoy above-average growth over the long run seems to be high. It has a wide range of popular brands in a number of different markets. This provides it with a wide economic moat which, alongside its growth potential, makes it an enticing income opportunity for the long term.

Peter Stephens owns shares of AstraZeneca and Unilever. The Motley Fool UK owns shares of and has recommended Unilever. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female couple boarding their plane at the airport to go on holiday.
Investing Articles

Can the Rolls-Royce share price reach £15.97 by the end of August?

The Rolls-Royce share price has had a solid run in the last year. Muhammad Cheema takes a look at whether…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Up 1,200% in 5 years, here’s why Nvidia could still be a brilliant value stock

An exciting new announcement that could reshape the PC industry has just pushed Nvidia stock... well, just about nowhere really.

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

How investing £4.50 a day could set you on the way to a £1,505 monthly second income

How can UK stocks with high dividend yields help investors earn a meaningful second income from the price of a…

Read more »

Investing Articles

Up 103% with a P/E of 261 — is this FTSE 100 stock still worth buying?

One FTSE 100 stock is quietly moving higher while most investors are still looking elsewhere — is the market missing…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

The smart money thinks AI stocks look risky — but is there still a chance to buy?

According to fund managers, the AI trade is getting crowded. But they still seem to think it’s the place to…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Barclays shares are 11% below their 52-week high. Could they be a bit of a bargain to consider?

Overpriced or one of the FTSE 100’s hidden gems? James Beard takes a closer look at how the market is…

Read more »

Stack of one pound coins falling over
Investing Articles

Down 65% but yielding 6.7% – is this beaten-down UK stock now a generational bargain?

Harvey Jones says this UK stock is one of the worst FTSE 100 performers but there are sound reasons to…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is this FTSE stock really 46% undervalued?

Analysts reckon this FTSE stock should be worth nearly 50% more. James Beard considers why there’s so much positivity surrounding…

Read more »